Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas. |
|
|
Press Release - ADVENTRX Pharmaceuticals, Inc. (ANX-NYSE Amex) |
|
|
“ADVENTRX stands out among its small cap peers because we expect to submit an NDA, the final regulatory hurdle to drug approval, this year. There is only a limited amount of work remaining before we submit that NDA, and we have both the financial and human capital to get there.” - Brian M. Culley, M.A., M.B.A. (ANX) (Interview published June 18, 2010) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | MARKETING SERVICES | HOME PAGE |
|
ADVENTRX Pharmaceuticals to Present at the
4TH Annual OneMedForum Business Development and Investment
Conference on January 11
SAN DIEGO, Jan. 4, 2011 /PRNewswire via COMTEX/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the 4th Annual OneMedForum Business Development and Investment Conference on Tuesday January 11, 2011 at 10:00 a.m. Pacific time, in the Renaissance room at the Sir Francis Drake Hotel in San Francisco, CA.
Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals web site at www.adventrx.com. An archived presentation will be available on the web site for 30 days. About ADVENTRX Pharmaceuticals ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are being developed to improve the performance of existing anti-cancer drugs by addressing limitations associated principally with their safety and use. More information can be found on the Company's web site at www.adventrx.com. SOURCE ADVENTRX Pharmaceuticals, Inc.
|
|
